Drugs / CDK-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05156229 | Sep 2021 → Aug 2022 | primary cutaneous T-cell non-Hodgkin lymphoma | Codiak BioSciences | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDK-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156229 ↗ |
| Route | Subcutaneous | “CDK-003 administered subcutaneously” NCT05156229 ↗ |